Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares traded up 2.1% on Friday . The company traded as high as $162.60 and last traded at $160.99, with a volume of 191,683 shares. The stock had previously closed at $157.69.

A number of research analysts have weighed in on the company. Cantor Fitzgerald reissued a “sell” rating and set a $60.00 price target on shares of Intercept Pharmaceuticals in a research note on Monday. Vetr lowered Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $81.50 target price on the stock. in a research report on Monday. Morgan Stanley reaffirmed a “sell” rating and issued a $80.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $218.00 target price (down from $219.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Finally, Oppenheimer Holdings Inc. cut their target price on Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating on the stock in a research report on Friday, August 5th. Five analysts have rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $177.67.

The stock’s market capitalization is $4.01 billion. The company has a 50-day moving average price of $154.12 and a 200-day moving average price of $137.76.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.69) by $0.55. During the same period in the previous year, the firm earned ($1.99) earnings per share. The company had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. The firm’s quarterly revenue was up 1140.4% on a year-over-year basis. Analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.39) EPS for the current fiscal year.

In other news, CEO Mark Pruzanski sold 714 shares of Intercept Pharmaceuticals stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total transaction of $103,608.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Lisa Bright sold 251 shares of Intercept Pharmaceuticals stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the transaction, the insider now directly owns 18,855 shares in the company, valued at $2,592,562.50. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have bought and sold shares of the company. BlackRock Advisors LLC boosted its position in Intercept Pharmaceuticals by 5.4% in the fourth quarter. BlackRock Advisors LLC now owns 125,274 shares of the biopharmaceutical company’s stock worth $18,710,000 after buying an additional 6,461 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock worth $5,468,000 after buying an additional 578 shares in the last quarter. New York State Common Retirement Fund boosted its position in Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock worth $5,586,000 after buying an additional 800 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock worth $2,367,000 after buying an additional 109 shares in the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.